Navigation Links
Trius Therapeutics Reports 2010 Second Quarter Results
Date:8/19/2010

SAN DIEGO, Aug. 19 /PRNewswire-FirstCall/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections, announced today its financial results for the three months ended June 30, 2010.

Revenues from federal research contracts for the three months ended June 30, 2010 increased to $2.1 million as compared to $1.2 million for the same period in 2009. For the six months ended June 30, 2010, total revenues were $3.6 million, as compared to $2.3 million for the same period in 2009. The increase in revenues during the three and six months ended June 30, 2010 was largely due to the award of the company's second federal research contract, a $29.5 million, four and a half-year contract from the Defense Threat Reduction Agency (DTRA). Trius' first federal contract was a $27.7 million, five-year contract from the National Institutes for Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH).

Total operating expenses for the three months ended June 30, 2010 were $4.5 million, as compared to $6.5 million for the same period in 2009. For the six months ended June 30, 2010, total operating expenses were $9.9 million, as compared to $14.2 million for the same period in 2009. The decrease in operating expenses during the three and six months ended June 30, 2010 was primarily the result of lower clinical trial expenses during the periods as the company finalized the Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA).

Trius ended the second quarter of 2010 with cash and cash equivalents totaling $10.4 million. On a pro forma basis, accounting for the net cash proceeds of its Initial Public Offering (IPO) which closed in August 2010 as of June 30, 2010, the company had cash and cash equivalents of $56.0 million. As of August 16, 2010, Trius had 23,554,766 shares outstanding.

"With the proceeds from our recent IPO and in accordance with the SPA recently granted to Trius by the FDA, Trius is poised to move torezolid phosphate into its first Phase 3 study for the treatment of acute bacterial skin and skin structure infections (ABSSSI)," said Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius.

About Trius Therapeutics Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company's first product candidate, torezolid phosphate, is an IV and orally administered second generation oxazolidinone being developed for the treatment of serious gram-positive infections, including those caused by MRSA. In addition to the company's torezolid phosphate clinical program, it is currently conducting two preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit www.triusrx.com.

Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding Trius' planned activities under the Phase 3 clinical trial for the oral dosage form of torezolid phosphate. Risks that contribute to the uncertain nature of the forward-looking statements include: Trius' ability to obtain additional financing; Trius' use of the net proceeds from the IPO; the accuracy of the company's estimates regarding expenses, future revenues and capital requirements; the success and timing of Trius' preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; the performance of third-party manufacturers; changes in Trius' plans to develop and commercialize its product candidates; Trius' ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Trius' most recently filed SEC documents, including its Registration Statement on Form S-1 that was originally filed with the United States Securities and Exchange Commission on November 6, 2009, and the amendments thereto, including those factors discussed under the caption "Risk Factors" in such filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trius undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Trius Therapeutics, Inc.
Statements of Operations
(In thousands except per share data)Three Months Ended June 30,Six Months Ended June 30,2010200920102009(Unaudited)(Unaudited)Revenues:Contract research and grants

$  2,084

$  1,203

$  3,570

$  2,288Collaborations

6

6Total revenues

2,084

1,209

3,570

2,294Operating expenses:Research and development

3,484

5,636

7,636

12,307General and administrative

1,021

857

2,231

1,853Total operating expenses

4,505

6,493

9,867

14,160Loss from operations

(2,421)

(5,284)

(6,297)

(11,866)Other income (expense):Interest income

13

31Interest expense

(391)

(8)

(794)

(17)Other income (expense)

471

(16)

475

(13)Total other income (expense)

80

(11)

(319)

1Net loss

(2,341)

(5,295)

(6,616)

(11,865)Accretion of deferred financing costs on redeemable convertible preferred stock

(7)

(7)

(15)

(14)Net loss attributable to common stockholders

$  (2,348)

$  (5,302)

$  (6,631)

$  (11,879)Net loss per share, basic and diluted

$  (2.69)

$  (7.49)

$  (7.74)

$  (17.27)Weighted-average shares outstanding, basic and diluted

872

708

857

688Trius Therapeutics, Inc.
Balance Sheets
(In thousands except share and per share data)June 30,
2010Pro Forma
June 30,
2010(1)December 31,
2009AssetsCurrent assets:Cash and cash equivalents

$  10,391

$  56,041

$  18,259Accounts receivable

1,840689Prepaid expenses and other current assets

343468Total current assets12,57419,416Property and equipment, net

551494Deferred IPO financing costs

2,2801,378Other assets

22590Total assets

$  15,630$  21,378Liabilities, convertible preferred stock and stockholders' equity (deficit)Current liabilities:Accounts payable

$  829$  608Accrued liabilities and other

804887Current portion of capital lease obligation

669Convertible notes payable

20,159

—Total current liabilities

21,7981,564Deferred revenue

238166Preferred stock warrant liability

185

661Convertible notes payable

—19,402Convertible preferred stock, $0.0001 par value:
 1,676,453 shares authorized at June 30, 2010 and
 December 31, 2009; 1,454,545 shares issued and
 outstanding at June 30, 2010 and December 31, 2009;
 and liquidation preference of $800 at June 30, 2010 and
 December 31, 2009

729

729Redeemable convertible preferred stock, $0.0001 par
 value: 101,168,185 shares authorized at June 30, 2010
 and December 31, 2009; 66,863,641 shares issued and
 outstanding at June 30, 2010 and December 31, 2009;
 and liquidation preference of $50,500 at June 30, 2010
 and December 31, 2009

50,368

50,353Stockholders' equity (deficit):Common stock, $0.0001 par value: 123,000,000
shares authorized at June 30, 2010 and
December 31, 2009; 967,580 and 968,230 shares
issued and outstanding at June 30, 2010 and
December 31, 2009 and 23,554,592 shares issued
and outstanding on a pro forma basis at June 30,
2010(1)

1

2

1Additional paid-in capital

2,203

122,350

1,763Accumulated deficit

(59,892)

(62,949)

(53,261)Total stockholders' equity (deficit)

(57,688)

59,403

(51,497)Total liabilities, convertible preferred stock and stockholders' equity (deficit)

$  15,630$  21,378

  1. The Pro forma June 30, 2010 balance sheet data reflects the sale of 10,000,000 shares of common stock in our IPO, based on the IPO price of $5.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us and the conversion of all outstanding shares of our preferred stock into an aggregate of 7,943,959 shares of our common stock, the conversion of outstanding principal and accrued interest on the secured convertible notes that we issued in November 2009, a beneficial conversion charge related to such conversion, and the issuance of an aggregate of 4,643,227 shares of our common stock upon such conversion, based on the IPO price of $5.00 per share, and assuming the occurrence of the conversion on August 6, 2010, and the reclassification of the preferred stock warrant liability to additional paid-in-capital upon the conversion of the warrants to purchase preferred stock into warrants to purchase common stock, all assumed as of June 30, 2010.


'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Trius Awarded $28 Million Contract to Develop Novel Antibiotics
2. Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board
3. Trius Therapeutics Awarded U.S. Department of Defense Contract to Develop Novel Antibiotics
4. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
5. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
7. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
8. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
9. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
10. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
11. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... India , May 3, 2016 /PRNewswire/ ... (DNA Chip (Genomics, Drug Discovery, Gene Expression) ... End user (Academics Institutes, Diagnostics Centers), Fabrication ... published by MarketsandMarkets, the market is expected ... from USD 7.63 Billion in 2015, growing ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... development, skill-building and compliance training platform on mobile devices, today released a new ... Regulatory Requirements for Medical Devices. The course is essential for owners or operators ...
(Date:5/3/2016)... ... May 03, 2016 , ... In a list published ... of the state’s 76 fastest-growing private companies; a small percentage of the state's 615,000+ ... organizations on the percent change in revenue from 2012 to 2015. , ...
(Date:5/3/2016)... Boston, Massachusetts (PRWEB) , ... May 03, 2016 ... ... communities will gather at Boston CEO 2016 on May 31st and June 1st ... off-the-record networking forum for leading executives in the life sciences, offering exclusive access ...
Breaking Biology Technology:
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):